Bessemer Group Inc. Buys 640,865 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Bessemer Group Inc. grew its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 451.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 782,856 shares of the company’s stock after acquiring an additional 640,865 shares during the period. Bessemer Group Inc. owned about 0.09% of Dr. Reddy’s Laboratories worth $12,361,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of RDY. Robeco Institutional Asset Management B.V. raised its position in Dr. Reddy’s Laboratories by 453.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock valued at $180,620,000 after purchasing an additional 9,373,412 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Dr. Reddy’s Laboratories by 382.9% during the fourth quarter. Renaissance Technologies LLC now owns 9,418,428 shares of the company’s stock valued at $148,717,000 after buying an additional 7,467,979 shares during the period. Aikya Investment Management Ltd raised its holdings in shares of Dr. Reddy’s Laboratories by 416.1% in the fourth quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company’s stock valued at $88,590,000 after acquiring an additional 4,523,303 shares in the last quarter. Vanguard Group Inc. lifted its stake in Dr. Reddy’s Laboratories by 397.2% in the fourth quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company’s stock worth $77,311,000 after acquiring an additional 3,911,404 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in Dr. Reddy’s Laboratories by 462.1% during the 4th quarter. JPMorgan Chase & Co. now owns 2,814,710 shares of the company’s stock worth $44,444,000 after acquiring an additional 2,313,987 shares in the last quarter. Hedge funds and other institutional investors own 3.85% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Nomura lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th.

Dr. Reddy’s Laboratories Trading Down 2.1 %

Shares of NYSE:RDY opened at $12.75 on Friday. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $10.64 billion, a PE ratio of 20.29 and a beta of 0.51. Dr. Reddy’s Laboratories Limited has a 12-month low of $12.26 and a 12-month high of $16.89. The business’s fifty day simple moving average is $13.21 and its 200-day simple moving average is $14.38.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, equities research analysts predict that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.